Mechanism of cytochrome P450‐3A inhibition by ketoconazole
暂无分享,去创建一个
Karthik Venkatakrishnan | David J Greenblatt | D. Greenblatt | J. Harmatz | K. Venkatakrishnan | Yanli Zhao | L. V. von Moltke | Michael H Court | Lisa L von Moltke | Su X Duan | Yanli Zhao | Jerold S Harmatz | Sarah J Parent | M. Court | S. Duan | Sarah J. Parent | David J. Greenblatt | Jerold S. Harmatz | Lisa L. von Moltke
[1] D. Greenblatt,et al. Clinical Studies of Drug–Drug Interactions: Design and Interpretation , 2010 .
[2] D. Greenblatt,et al. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[3] S D Hall,et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.
[4] G. Miller,et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.
[5] Hayley S. Brown,et al. Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination , 2007, Drug Metabolism and Disposition.
[6] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.
[7] A. D. Rodrigues,et al. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[8] D. Greenblatt,et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[9] A. Galetin,et al. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[10] D. Greenblatt,et al. ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO , 2005, Drug Metabolism and Disposition.
[11] J B Houston,et al. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.
[12] H. Yamazaki,et al. Heterotropic cooperativity in oxidation mediated by cytochrome p450. , 2008, Current drug metabolism.
[13] R. Obach,et al. Inactivation of Human Cytochrome P450 Enzymes and Drug–Drug Interactions , 2010 .
[14] D. Greenblatt,et al. In Vitro Approaches to Anticipating Clinical Drug Interactions , 2007 .
[15] Aleksandra Galetin,et al. Modelling atypical CYP3A4 kinetics: principles and pragmatism. , 2005, Archives of biochemistry and biophysics.
[16] D. Greenblatt,et al. Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[17] L. Wienkers,et al. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[18] J. Houston,et al. The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[19] P. Dansette,et al. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. , 2005, Current drug metabolism.
[20] D. Greenblatt,et al. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. , 2000, The Journal of pharmacology and experimental therapeutics.
[21] H. Gutfreund,et al. Enzyme kinetics , 1975, Nature.
[22] F. Guengerich,et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.
[23] Kiyomi Ito,et al. CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005, Journal of Pharmacology and Experimental Therapeutics.
[24] D. Greenblatt,et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. , 1994, British journal of clinical pharmacology.
[25] D. Greenblatt,et al. Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents , 1996, Journal of clinical pharmacology.
[26] Karthik Venkatakrishnan,et al. Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.
[27] D. Greenblatt,et al. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. , 1993, Pharmacology.
[28] Amy Roe,et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[29] J. Houston,et al. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[30] J. Houston,et al. In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: Qualitative relationships, quantitative predictions, and the rank‐order approach , 2005, Clinical pharmacology and therapeutics.
[31] D. Greenblatt,et al. Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.
[32] H. Hachad,et al. Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. , 2007, Current drug metabolism.
[33] Y. Nabuchi,et al. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. , 2009, Drug metabolism and pharmacokinetics.
[34] A. D. Rodrigues,et al. Enzyme- and transporter-based drug-drug Interactions : progress and future challenges , 2010 .
[35] D. Greenblatt,et al. Apparent mechanism‐based inhibition of human CYP3A in‐vitro by lopinavir , 2003, The Journal of pharmacy and pharmacology.
[36] D. Greenblatt,et al. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.
[37] D. Greenblatt,et al. In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction , 1994, Journal of clinical pharmacology.
[38] J. Halpert,et al. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] J S Harmatz,et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.
[40] P. Thomas,et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[41] D. Greenblatt,et al. Chapter 11:The CYP3 Family , 2008 .